Figure I: Participant Flow Diagram

assessed for eligibility (n=102)

- Excluded (n=4) failed inclusion criteria, no adequate histology, hereditary VHL-tumor

ccRCC without PDL1 expression (n=29)

- VHL status
  - Inactivated VHL (n=25)
  - Non inactivated VHL (n=4)

ccRCC with PDL1 expression (n=69)

- VHL status
  - Inactivated VHL (n=40)
  - Non inactivated VHL (n=29)
Figure II: PDL1 immunostaining
A, B, C) Absence of PDL1, IHC x100
D, E, F) Low expression of PDL1, IHC x100
G, H) Moderate expression of PDL1, IHC x100
I, J, K) High expression of PDL1, IHC x100
Figure III: sarcomatoid component. HES x100 (A et B)

Figure IV: CAIX immunostaining:
A) Absence of CAIX staining. IHC x100
B) Membranous expression of CAIX in 100% tumor cells, IHC x100

Figure V: PAR3 immunostaining
A) Membranous expression of PAR3, IHC x100
B) Membranous and cytoplasmic expression of PAR3, IHC x100
Figure VI: VEGFA immunostaining
A) Absence of VEGFA staining, IHC x100
B) Cytoplasmic expression of VEGFA in 100% tumor cells, IHC x100

Figure VII: PD1 immunostaining
A) Absence of PD1 expression, IHC x100
B) Dense PD-1 expression in tumor-infiltrating lymphocytes, IHC x100